2AB Stock Chart & Stats
€0.54
>-€0.01(-0.99%)
At close: 4:00 PM EDT
€0.54
>-€0.01(-0.99%)
Day’s Range― - ―
52-Week Range€0.45 - €1.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€26.31M
Enterprise Value-€22.31
Total Cash (Recent Filing)€59.30M
Total Debt (Recent Filing)€10.29M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Nov 05, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding40,848,892
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.18Price Target Upside859.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageLow debt relative to equity limits interest and refinancing pressure, giving Barinthus greater flexibility to fund clinical programs or pursue partnerships while operating as a development-stage biotechnology company.
Proprietary Immunotherapy PlatformsA proprietary platform can support multiple clinical programs and create opportunities for licensing or collaboration beyond a single asset. This may improve strategic flexibility if the technology produces differentiated immune responses.
Strategic Merger And Listing ResetThe proposed merger could reshape the company’s capital structure and investor access while addressing Nasdaq minimum-price requirements through a new parent listing. Successful completion may provide a clearer platform for future financing and development.
Bears Say
No Current Revenue Or Stable ProfitabilityThe absence of recurring product or collaboration revenue leaves the company dependent on future clinical and regulatory success. Persistent losses also reduce earnings visibility and make operating performance difficult to assess over the next several quarters.
Persistent Cash BurnOngoing negative cash generation means Barinthus must continue funding research and operations through financing, partnerships, or asset transactions. This creates execution risk and can constrain the pace of clinical development if capital becomes less available.
Material Equity ErosionThe substantial decline in equity reflects prolonged losses and consumption of capital, reducing the balance-sheet cushion available for clinical development. Future financing could also lead to dilution if internal cash resources remain insufficient.
Barinthus Biotherapeutics News
2AB FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was €0.45 and its highest was €1.30 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is €26.31M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 67 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Aug 06, 2026. The company reported -€0.223 earnings per share for the quarter, beating the consensus estimate of -€0.24 by €0.017.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Undervalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.22.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -€0.223 in its last earnings report, beating expectations of -€0.24. Following the earnings report the stock price went up 0.429%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in DE:2AB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
2AB Stock 12 Month Forecast
Average Price Target
€5.18
▲(859.00% Upside)
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―